Sentiment-Signal
26,4
Bearisch
Composite Score (0–100)
Insider (25%)
24.9
1 Insider, 1,6M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors.On April 14, |
| 19.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors. On August 15, |
| 07.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 13.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 11.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors. On July 10 |
| 05.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Unternehmen & Branche
| Name | Adicet Bio, Inc. |
|---|---|
| Ticker | ACET |
| CIK | 0001720580 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 74,2 Mio. USD |
| Beta | 1,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -116,803,000 | -16.95 | 192,355,000 | 159,210,000 | |
| 2025-09-30 | 10-Q | -26,856,000 | -0.29 | 140,479,000 | 109,142,000 | |
| 2025-06-30 | 10-Q | -31,217,000 | -0.34 | 162,972,000 | 133,372,000 | |
| 2025-03-31 | 10-Q | -28,214,000 | -0.31 | 191,271,000 | 161,446,000 | |
| 2024-12-31 | 10-K | -117,122,000 | -21.33 | 220,219,000 | 186,609,000 | |
| 2024-09-30 | 10-Q | -30,478,000 | -0.34 | 245,962,000 | 211,531,000 | |
| 2024-06-30 | 10-Q | -29,901,000 | -0.33 | 268,842,000 | 235,111,000 | |
| 2024-03-31 | 10-Q | -28,016,000 | -0.35 | 293,095,000 | 258,804,000 | |
| 2023-12-31 | 10-K | -142,658,000 | -3.31 | 207,295,000 | 170,175,000 | |
| 2023-09-30 | 10-Q | -49,885,000 | -1.16 | 233,257,000 | 194,677,000 | |
| 2023-06-30 | 10-Q | -32,403,000 | -0.75 | 277,633,000 | 239,061,000 | |
| 2023-03-31 | 10-Q | -30,881,000 | -0.72 | 304,974,000 | 266,215,000 | |
| 2022-12-31 | 10-K | -69,790,000 | -1.70 | 330,690,000 | 292,338,000 | |
| 2022-12-31 | 10-Q | 4,618,000 | 330,690,000 | 292,338,000 | ||
| 2022-09-30 | 10-Q | -21,996,000 | -0.53 | 354,303,000 | 317,658,000 | |
| 2022-06-30 | 10-Q | -22,538,000 | -0.56 | 329,904,000 | 293,267,000 | |
| 2022-03-31 | 10-Q | 4,618,000 | 0.10 | 340,451,000 | 311,084,000 | |
| 2021-12-31 | 10-K | -61,999,000 | -2.00 | 338,938,000 | 303,129,000 | |
| 2021-09-30 | 10-Q | -14,013,000 | -0.44 | 257,195,000 | 217,224,000 | |
| 2021-06-30 | 10-Q | -10,854,000 | -0.34 | 268,778,000 | 228,341,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -32,523 | 6.29 | -204,569.67 | -25,3% | |
| 2026-04-08 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -40,416 | 6.52 | -263,512.32 | -32,6% | |
| 2026-04-07 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -2,400 | 6.38 | -15,312.00 | -1,9% | |
| 2026-04-07 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -29,319 | 6.53 | -191,453.07 | -23,7% | |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Open Market Purchase | 74,751 | 7.27 | 543,439.77 | +67,2% | |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Open Market Purchase | 74,268 | 7.21 | 535,472.28 | +66,2% | |
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Open Market Purchase | 74,577 | 7.04 | 525,022.08 | +64,9% | |
| 2025-10-08 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Purchase | 3,500,000 | 1.00 | 3,500,000.00 | +432,8% | |
| 2025-10-08 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Purchase | 1,500,000 | 1.00 | 1,500,000.00 | +185,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.